Trace amine associated receptor 1: predicted effects of single nucleotide variants on structure-function in geographically diverse populations

Britto Shajan,Shashikanth Marri,Tarun Bastiampillai,Karen J. Gregory,Shane D. Hellyer,Pramod C. Nair

DOI: https://doi.org/10.1186/s40246-024-00620-w

2024-06-13

Human Genomics

Abstract:Trace Amine Associated Receptor 1 (TAAR1) is a novel pharmaceutical target under investigation for the treatment of several neuropsychiatric conditions. TAAR1 single nucleotide variants (SNV) have been found in patients with schizophrenia and metabolic disorders. However, the frequency of variants in geographically diverse populations and the functional effects of such variants are unknown. In this study, we aimed to characterise the distribution of TAAR1 SNVs in five different WHO regions using the Database of Genotypes and Phenotypes (dbGaP) and conducted a critical computational analysis using available TAAR1 structural data to identify SNVs affecting ligand binding and/or functional regions. Our analysis shows 19 orthosteric, 9 signalling and 16 micro-switch SNVs hypothesised to critically influence the agonist induced TAAR1 activation. These SNVs may non-proportionally influence populations from discrete regions and differentially influence the activity of TAAR1-targeting therapeutics in genetically and geographically diverse populations. Notably, our dataset presented with orthosteric SNVs D103 3.32 N (found only in the South-East Asian Region and Western Pacific Region) and T194 5.42 A (found only in South-East Asian Region), and 2 signalling SNVs (V125 3.54 A/T252 6.36 A, found in African Region and commonly, respectively), all of which have previously demonstrated to influence ligand induced functions of TAAR1. Furthermore, bioinformatics analysis using SIFT4G, MutationTaster 2, PROVEAN and MutationAssessor predicted all 16 micro-switch SNVs are damaging and may further influence the agonist activation of TAAR1, thereby possibly impacting upon clinical outcomes. Understanding the genetic basis of TAAR1 function and the impact of common mutations within clinical populations is important for the safe and effective utilisation of novel and existing pharmacotherapies.

genetics & heredity

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to understand the distribution of single - nucleotide variants (SNVs) in the human TAAR1 (Trace Amine Associated Receptor 1) gene among populations in different geographical regions and their potential impacts on the structure and function of TAAR1. Specifically, the research aims to:

1. **Identify and characterize the geographical distribution of TAAR1 SNVs**: By using the Database of Genotypes and Phenotypes (dbGaP) database, the researchers identified the distribution of TAAR1 SNVs in five different WHO regions (the African region, the Southeast Asian region, the American region, the European region, and the Western Pacific region).

2. **Analyze the functional effects of TAAR1 SNVs**: Using the existing TAAR1 structure data, predict the impacts of these SNVs on ligand - binding sites (orthosteric sites), signalling domains, and micro - switch domains through computational methods. In particular, the study focuses on 19 orthosteric - binding SNVs, 9 signalling SNVs, and 16 micro - switch SNVs that may severely affect TAAR1 activation.

3. **Evaluate the potential impacts of genetic variations on the efficacy of TAAR1 - targeted therapeutic drugs**: The study found that certain SNVs may disproportionately affect populations in specific regions and may differentially affect the activity of TAAR1 - targeted therapeutic drugs in genetically and geographically diverse clinical populations. For example, the two orthosteric - binding SNVs D1033.32N and T1945.42A are only found in Southeast Asia and the Western Pacific region, while the two signalling SNVs V1253.54A and T2526.36A are common and prevalent in the African region respectively.

Through these analyses, the study provides important information for understanding the genetic basis of TAAR1 function and the impacts of common mutations on clinical populations, which is crucial for the safe and effective use of new and existing drugs.